NO20074062L - Anvendelse av Lactobacillus Rhamnosus GG i kombinasjon med en langkjedet flerumettet fettesyre for behandling, forhindring eller reduksjon av systemisk inflammasjon i et barnemat-matet spebarn - Google Patents

Anvendelse av Lactobacillus Rhamnosus GG i kombinasjon med en langkjedet flerumettet fettesyre for behandling, forhindring eller reduksjon av systemisk inflammasjon i et barnemat-matet spebarn

Info

Publication number
NO20074062L
NO20074062L NO20074062A NO20074062A NO20074062L NO 20074062 L NO20074062 L NO 20074062L NO 20074062 A NO20074062 A NO 20074062A NO 20074062 A NO20074062 A NO 20074062A NO 20074062 L NO20074062 L NO 20074062L
Authority
NO
Norway
Prior art keywords
prevention
reduction
treatment
combination
baby
Prior art date
Application number
NO20074062A
Other languages
English (en)
Inventor
Robert J Mcmahon
Udo Herz
Josef Neu
Original Assignee
Mjn Us Holdings Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mjn Us Holdings Llc filed Critical Mjn Us Holdings Llc
Publication of NO20074062L publication Critical patent/NO20074062L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Det beskrives en ny anvendelse av LGG i kombinasjon med minst én LCPUFA ved fremstillingen av et medikament for behandling, forebyggelse eller reduksjon av systemisk inflammasjon i et kunstig ernært spedbarn.
NO20074062A 2005-04-15 2007-08-07 Anvendelse av Lactobacillus Rhamnosus GG i kombinasjon med en langkjedet flerumettet fettesyre for behandling, forhindring eller reduksjon av systemisk inflammasjon i et barnemat-matet spebarn NO20074062L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/106,794 US20060233762A1 (en) 2005-04-15 2005-04-15 Method for treating or preventing systemic inflammation in formula-fed infants
PCT/US2006/010415 WO2006113034A1 (en) 2005-04-15 2006-03-22 Use of lactobacillus rhamnosus gg in combination with a long chain polyunsaturated fatty acid for the treatment, prevention or reduction of systemic inflammation in a formula-fed infant

Publications (1)

Publication Number Publication Date
NO20074062L true NO20074062L (no) 2007-11-13

Family

ID=36658778

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20074062A NO20074062L (no) 2005-04-15 2007-08-07 Anvendelse av Lactobacillus Rhamnosus GG i kombinasjon med en langkjedet flerumettet fettesyre for behandling, forhindring eller reduksjon av systemisk inflammasjon i et barnemat-matet spebarn

Country Status (13)

Country Link
US (2) US20060233762A1 (no)
EP (1) EP1868596B1 (no)
KR (1) KR101277050B1 (no)
CN (1) CN101146525A (no)
BR (1) BRPI0609401A8 (no)
CA (1) CA2599618C (no)
ES (1) ES2738006T3 (no)
MX (1) MX2007010804A (no)
MY (1) MY172984A (no)
NO (1) NO20074062L (no)
RU (1) RU2416401C2 (no)
TW (1) TWI372058B (no)
WO (1) WO2006113034A1 (no)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7572474B2 (en) * 2005-06-01 2009-08-11 Mead Johnson Nutrition Company Method for simulating the functional attributes of human milk oligosaccharides in formula-fed infants
US20090258823A1 (en) * 2006-12-08 2009-10-15 George Caroline L S Composition and methods for the prevention and treatment of gastrointestinal infections
WO2008106373A1 (en) * 2007-02-28 2008-09-04 Mead Johnson Nutrition Company Product containing inactivated probiotic for children or infants
US8343753B2 (en) 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
WO2009058799A1 (en) * 2007-11-01 2009-05-07 Wake Forest University School Of Medicine Compositions and methods for prevention and treatment of mammalian diseases
US9439885B2 (en) * 2008-06-03 2016-09-13 Mead Johnson Nutrition Company Method for inhibiting the growth of bacteria
US8498729B2 (en) 2008-08-29 2013-07-30 Smp Logic Systems Llc Manufacturing execution system for use in manufacturing baby formula
EP2525811B2 (en) * 2010-01-19 2019-02-27 Abbott Laboratories A composition comprising lactobacillus rhamnosus hn001 and prebiotics for use in the treatment of allergic lung disease
WO2016204271A1 (ja) * 2015-06-19 2016-12-22 国立大学法人静岡大学 免疫機能発達促進剤及び成長促進剤
CN108715822B (zh) * 2018-06-13 2021-09-03 吉林省农业科学院 一株鼠李糖乳杆菌及其在制备抗抑郁产品中的应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4839281A (en) * 1985-04-17 1989-06-13 New England Medical Center Hospitals, Inc. Lactobacillus strains and methods of selection
US5840318A (en) * 1993-05-11 1998-11-24 Immunom Technologies, Inc. Methods and compositions for modulating immune systems of animals
FI104465B (fi) * 1995-06-14 2000-02-15 Valio Oy Proteiinihydrolysaatteja allergioiden hoitamiseksi tai estämiseksi, niiden valmistus ja käyttö
JPH092959A (ja) * 1995-06-16 1997-01-07 Yakult Honsha Co Ltd ＩｇＥ抗体産生抑制剤および抗アレルギー剤
ES2219871T3 (es) * 1997-02-21 2004-12-01 Abbott Laboratories Procedimiento y composiciones que sirven para limitar la frecuencia de la enterocolitis necrotizante del recien nacido.
US6203797B1 (en) * 1998-01-06 2001-03-20 Stephen C. Perry Dietary supplement and method for use as a probiotic, for alleviating the symptons associated with irritable bowel syndrome
US6461607B1 (en) * 1998-08-24 2002-10-08 Ganeden Biotech, Inc. Probiotic, lactic acid-producing bacteria and uses thereof
PL348810A1 (en) * 1998-12-15 2002-06-17 American Home Prod Method and composition for the maintenance and restitution of gut integrity
US6696057B1 (en) * 1999-09-22 2004-02-24 Lacpro Industries, Inc. Composition and method for treatment of gastrointestinal disorders and hyperlipidemia
US20010047036A1 (en) * 1999-12-17 2001-11-29 Vanderhoof Jon A. Composition for improving the proliferative response during adaptation of the gastrointestinal tract and use in short bowel syndrome
US6613549B2 (en) * 2000-02-10 2003-09-02 Urex Biotech, Inc. Probiotic therapy for newborns
AUPQ761200A0 (en) * 2000-05-19 2000-06-15 Hunter Immunology Limited Compositions and methods for treatment of mucosal infections
JP2003535903A (ja) * 2000-06-19 2003-12-02 ミューコプロテック・プロプライエタリー・リミテッド プロバイオティックを用いた、粘膜表面での細菌またはウイルス感染の免疫療法または治療、およびそのための組成物
FI110668B (fi) * 2000-06-20 2003-03-14 Aboatech Ab Oy Probioottien käyttö atooppisten sairauksien primaariseen ehkäisyyn
FI109602B (fi) * 2001-01-25 2002-09-13 Valio Oy Probioottiyhdistelmä
EP1239032A1 (en) * 2001-03-02 2002-09-11 Société des Produits Nestlé S.A. Lactic acid bacteria as agents for treating and preventing allergy
JP3853673B2 (ja) * 2001-03-09 2006-12-06 森永乳業株式会社 Ｃ型慢性肝炎治療剤
EP1364586A1 (en) * 2002-05-24 2003-11-26 Nestec S.A. Probiotics and oral tolerance
US7862808B2 (en) * 2004-07-01 2011-01-04 Mead Johnson Nutrition Company Method for preventing or treating respiratory infections and acute otitis media in infants using Lactobacillus rhamnosus LGG and Bifidobacterium lactis Bb-12

Also Published As

Publication number Publication date
KR20080025660A (ko) 2008-03-21
BRPI0609401A2 (pt) 2010-03-30
MY172984A (en) 2019-12-17
CN101146525A (zh) 2008-03-19
CA2599618C (en) 2015-04-28
ES2738006T3 (es) 2020-01-17
US20060233762A1 (en) 2006-10-19
RU2007133444A (ru) 2009-05-20
US20070009495A1 (en) 2007-01-11
EP1868596A1 (en) 2007-12-26
CA2599618A1 (en) 2006-10-26
BRPI0609401A8 (pt) 2018-03-13
RU2416401C2 (ru) 2011-04-20
TW200716146A (en) 2007-05-01
KR101277050B1 (ko) 2013-06-25
WO2006113034A1 (en) 2006-10-26
MX2007010804A (es) 2007-09-26
EP1868596B1 (en) 2019-05-15
TWI372058B (en) 2012-09-11

Similar Documents

Publication Publication Date Title
NO20074062L (no) Anvendelse av Lactobacillus Rhamnosus GG i kombinasjon med en langkjedet flerumettet fettesyre for behandling, forhindring eller reduksjon av systemisk inflammasjon i et barnemat-matet spebarn
WO2004112776A3 (en) Inflammatory disease treatment
WO2004106486A3 (en) Oxidized lipids and uses thereof in the treatment of inflammatory diseases and disorders
WO2004064716A3 (en) Eicosapentaenoic acid and docosapentaenoic acid for treating inflammatory disorders
WO2010070675A3 (en) Topical formulation(s) for the treatment of inflammation, skin and mucosal disorders and other diseases thereof
WO2007115305A3 (en) Oral dosage forms including an antiplatelet agent and an acid inhibitor
WO2007067968A3 (en) Effects of inhibitors of fgfr3 on gene transcription
MX2008001503A (es) Composicion cosmetica o dermatologica para la prevencion o el tratamiento de piel sensible o seca.
WO2005076924A3 (en) Agents for sequestering serum aging factors and uses therefore
BRPI0916693A2 (pt) uso de uma quantidade eficaz de pelo menos um microorganismo probiótico, composição cosmética e/ou dermatológica, e, método de tratamento cosmético
WO2010068794A3 (en) Hif inhibitors and use thereof
DK1071417T3 (da) Anvendelse af cannabidiol som anti-inflammatorisk middel
ATE511753T1 (de) Postnatale stammzellen und deren verwendungen
MX352328B (es) Formulaciones orales de ester de testosterona y metodos para el tratamiento de la deficiencia de testosterona que comprende estos.
WO2005023185A3 (en) Pharmaceutical compositions and method of using levodopa and carbidopa
AU2002302587A1 (en) Acne treatment with lipooxigenase inhibitors
ES2356883A1 (es) Composicion para el tratamiento del dolor y/o la inflamacion.
WO2007081878A8 (en) Indoleamine 2,3-dioxygenase pathways in the generation of regulatory t cells
WO2005112915A3 (en) Decrease in oxidative stress status through the administration of natural products and pharmaceutical drugs
BRPI1010369B8 (pt) composição cosmética em forma de nanoemulsão óleo-em-água e uso de uma composição
ECSP11011076A (es) Tratamiento de trastornos cognitivos con (r)-7-cloro-n-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida y sales farmacéuticamente aceptables de la misma
BRPI0514600A (pt) métodos para a fabricação de um composto, para a purificação de um composto, para o tratamento de um indivìduo tendo uma condição neoplástica, tendo carcinoma de célula escamosa, e tendo carcinoma de célula basal, para a redução ou prevenção da ocorrência de uma condição neoplástica em um indivìduo, e para a redução de triglicerìdeos no soro em um indivìduo, composto, e, composição farmacêutica
WO2010077339A3 (en) β-ARRESTIN EFFECTORS AND COMPOSITIONS AND METHODS OF USE THEREOF
WO2006090388A3 (en) Fruit cell culture extract for treating inflammation
EP2340724A3 (en) Treatment of stressed patients

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: MJN U.S. HOLDINGS LLC, US

FC2A Withdrawal, rejection or dismissal of laid open patent application